

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Concerns were raised about access to stereotactic radiotherapy varying across regions. However, the committee did not consider this an equality issue that it could address, because stereotactic radiotherapy is not a comparator in this appraisal and is expected to be used alongside tucatinib combination.

Concerns were also raised about the higher prevalence of breast cancer in women, particularly black women, than in men. However, issues relating to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal. The committee appraised tucatinib combination for the population in its marketing authorisation

Concerns were raised over accessibility to trastuzumab with capecitabine in the NHS. It is beyond committees remit to make judgements about appropriateness of standard care in the NHS.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]

Issue date: March 2022

<p>specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?</p>
<p>NA</p>

<p>3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?</p>
<p>NA</p>

<p>4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?</p>
<p>NA</p>

<p>5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?</p>
<p>NA</p>

Approved by Associate Director (name): Henry Edwards

Date: 08/03/22